Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials
In brief
JAK inhibitors achieve 75% vitiligo clearance in fivefold more patients
In a meta-analysis of nine randomized trials involving 1,826 people, JAK inhibitor therapy produced a 75% improvement in facial vitiligo scores about five times more often than placebo. The drugs were similarly safe to comparators, and topical ruxolitinib is now supported as first-line for limited facial disease, while oral agents await longer safety data.
- Journal
- The Journal of dermatological treatment (Q1)
- Published
- 28 August 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Ziyi Lin, Yi Chen, Jingpeng Chen, Yongxiang Long, Changxia Xiong, Xingwu Duan, et al.
- PMID
- 42664062
- DOI
- 10.1080/09546634.2026.2724628
Why clinicians should know about it
- Picked for Dermatology (top studies of the week, 30 August 2026): JAK inhibitors effective for vitiligo; RCT meta‑analysis
Abstract
Purpose: Janus kinase (JAK) inhibitors are a promising therapeutic option for vitiligo, but previous meta-analyses have focused mainly on topical ruxolitinib versus placebo. Newer randomized controlled trials (RCTs) evaluating oral agents and head-to-head comparisons with active treatments have not been comprehensively synthesized. Materials and methods: We searched PubMed, Embase, the Cochrane Library, and Web of Science to 11 March 2026. Eligible RCTs evaluated JAK inhibitor monotherapy versus placebo or active comparators. Two reviewers screened records, extracted data, and assessed risk of bias using RoB 2.0. The primary outcome was F-VASI75. Meta-analyses used fixed-effect or random-effects models. GRADE assessed certainty of evidence. Results: Nine RCTs (1826 patients) were included. JAK inhibitors increased F-VASI75 versus placebo (RR 4.59, 95% CI 3.20-6.59; p < 0.001). For F-VASI50, they were superior to tacrolimus (RR 1.88, 95% CI 1.02-3.45) but not significantly different from dexamethasone (RR 2.17, 95% CI 0.95-4.94). Serious adverse events were comparable between groups (RR 1.15, 95% CI 0.57-2.33). Evidence certainty was moderate. Conclusions: JAK inhibitors are effective and well tolerated for vitiligo. Topical ruxolitinib is supported as a first-line option for limited facial disease; oral agents show promise but require longer-term safety data.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.